Compugen Ltd
CGEN Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2016โFY2025
Revenue
Total sales reported in the income statement.
$72.8M
161.1%
vs prior year
Operating margin
Operating income as a share of revenue.
43.1%
96.5ย pts
Net income
Profit after all expenses, interest and tax.
$35.3M
Free cash flow
Cash from operations minus capital spending.
$31.3M
36.7%
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ
Market cap
Last close times the latest diluted share count, so it is approximate.
โ
P/E
Last close divided by diluted earnings per share over the last four quarters.
โ
On $0.38 EPS (TTM)
What Compugen Ltd does
No business description yet.
- Legal name
- COMPUGEN LTD
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F ยท Mar 2, 2026
- Accession ยท CIK
- 0001178913-26-000663
0001119774
Revenue and margins
Compugen Ltd had $72.8M of revenue in fiscal 2025, up 161.1% on the year before.
FY16
Revenue $0.7M
FY17
Revenue โ
FY18
Revenue $17.8M
FY19
Revenue โ
FY20
Revenue $2.0M
FY21
Revenue $6.0M
FY22
Revenue $7.5M
FY23
Revenue $33.5M
FY24
Revenue $27.9M
FY25
Revenue $72.8M
FY16
Gross 68.7%
Operating โ4,576.3%
Net โ4,425.0%
FCF โ3,148.6%
FY17
Gross โ
Operating โ
Net โ
FCF โ
FY18
Gross 94.2%
Operating โ130.5%
Net โ127.0%
FCF โ75.6%
FY19
Gross โ
Operating โ
Net โ
FCF โ
FY20
Gross 97.0%
Operating โ1,574.8%
Net โ1,484.9%
FCF โ1,424.3%
FY21
Gross 88.7%
Operating โ584.6%
Net โ570.1%
FCF โ383.1%
FY22
Gross 87.0%
Operating โ471.7%
Net โ449.3%
FCF โ461.2%
FY23
Gross 94.0%
Operating โ38.8%
Net โ56.1%
FCF โ107.8%
FY24
Gross 71.5%
Operating โ53.4%
Net โ51.1%
FCF 177.6%
FY25
Gross 87.3%
Operating 43.1%
Net 48.6%
FCF 43.1%
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY16
Net income โ$31.5M
FY17
Net income โ$37.1M
FY18
Net income โ$22.6M
FY19
Net income โ$27.3M
FY20
Net income โ$29.7M
FY21
Net income โ$34.2M
FY22
Net income โ$33.7M
FY23
Net income โ$18.8M
FY24
Net income โ$14.2M
FY25
Net income $35.3M
FY16
Diluted EPS โ$0.62
FY17
Diluted EPS โ$0.72
FY18
Diluted EPS โ$0.41
FY19
Diluted EPS โ$0.43
FY20
Diluted EPS โ$0.37
FY21
Diluted EPS โ$0.41
FY22
Diluted EPS โ$0.39
FY23
Diluted EPS โ$0.21
FY24
Diluted EPS โ$0.16
FY25
Diluted EPS $0.38
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY16
Return on capital โ
Return on equity โ49.6%
Return on assets โ44.3%
FY17
Return on capital โ
Return on equity โ79.9%
Return on assets โ67.5%
FY18
Return on capital โ
Return on equity โ67.9%
Return on assets โ49.2%
FY19
Return on capital โ
Return on equity โ72.4%
Return on assets โ51.1%
FY20
Return on capital โ
Return on equity โ37.6%
Return on assets โ30.9%
FY21
Return on capital โ
Return on equity โ30.2%
Return on assets โ25.3%
FY22
Return on capital โ
Return on equity โ36.5%
Return on assets โ29.8%
FY23
Return on capital โ
Return on equity โ26.2%
Return on assets โ17.4%
FY24
Return on capital โ
Return on equity โ23.6%
Return on assets โ12.0%
FY25
Return on capital โ
Return on equity 44.8%
Return on assets 26.0%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was $31.3M in fiscal 2025, 43.1% of revenue. Cash from operations minus capital spending.
FY16
Free cash flow โ$22.4M
FY17
Free cash flow โ$31.0M
FY18
Free cash flow โ$13.4M
FY19
Free cash flow โ$28.0M
FY20
Free cash flow โ$28.5M
FY21
Free cash flow โ$23.0M
FY22
Free cash flow โ$34.6M
FY23
Free cash flow โ$36.1M
FY24
Free cash flow $49.5M
FY25
Free cash flow $31.3M
FY16
Cash from operations โ$19.8M
Capital spending $2.6M
FY17
Cash from operations โ$30.7M
Capital spending $0.4M
FY18
Cash from operations โ$13.3M
Capital spending $0.2M
FY19
Cash from operations โ$27.9M
Capital spending $0.2M
FY20
Cash from operations โ$28.3M
Capital spending $0.2M
FY21
Cash from operations โ$22.7M
Capital spending $0.3M
FY22
Cash from operations โ$34.1M
Capital spending $0.5M
FY23
Cash from operations โ$35.9M
Capital spending $0.2M
FY24
Cash from operations $49.6M
Capital spending $0.1M
FY25
Cash from operations $31.6M
Capital spending $0.3M
Cash from operations
Capital spending
Dividends, buybacks and share count
Compugen Ltd returned โ to shareholders in fiscal 2025. The diluted share count rose 4.8%.
FY16
Dividends โ
Buybacks โ
FY17
Dividends โ
Buybacks โ
FY18
Dividends โ
Buybacks โ
FY19
Dividends โ
Buybacks โ
FY20
Dividends โ
Buybacks โ
FY21
Dividends โ
Buybacks โ
FY22
Dividends โ
Buybacks โ
FY23
Dividends โ
Buybacks โ
FY24
Dividends โ
Buybacks โ
FY25
Dividends โ
Buybacks โ
Dividends
Buybacks
FY16
Diluted shares 0.05B
FY17
Diluted shares 0.05B
FY18
Diluted shares 0.06B
FY19
Diluted shares 0.06B
FY20
Diluted shares 0.08B
FY21
Diluted shares 0.08B
FY22
Diluted shares 0.09B
FY23
Diluted shares 0.09B
FY24
Diluted shares 0.09B
FY25
Diluted shares 0.09B
Balance sheet
Cash, debt and the ratios that show how comfortably Compugen Ltd can carry it.
FY16
Cash $9.7M
Debt โ
FY17
Cash $25.5M
Debt โ
FY18
Cash $5.9M
Debt โ
FY19
Cash $9.2M
Debt โ
FY20
Cash $7.1M
Debt โ
FY21
Cash $7.8M
Debt โ
FY22
Cash $11.1M
Debt โ
FY23
Cash $25.6M
Debt โ
FY24
Cash $41.9M
Debt โ
FY25
Cash $99.9M
Debt โ
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $7.8M | $11.1M | $25.6M | $41.9M | $99.9M |
| Current ratio | 7.2x | 7.2x | 4.4x | 5.3x | 6.6x |
| Quick ratio | 7.2x | 7.2x | 4.4x | 5.3x | 6.6x |
| Total assets | $132M | $94.2M | $121M | $115M | $157M |
| Total liabilities | $25.5M | $16.5M | $55.8M | $60.1M | $53.8M |
| Shareholders' equity | $107M | $77.7M | $65.6M | $54.9M | $103M |
| Net debt (โ = net cash) | โ | โ | โ | โ | โ |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| F-score | โ / 3 | โ / 6 | โ / 6 | โ / 6 | โ / 6 | 2 / 8 | 2 / 8 | 3 / 8 | 4 / 8 | 6 / 8 |
| Accruals ratio | โ16.4% | โ11.7% | โ20.3% | 1.0% | โ1.4% | โ8.5% | 0.4% | 15.9% | โ54.0% | 2.7% |
| Altman Z'' | โ1.40 | โ24.94 | โ16.25 | โ18.06 | 1.74 | โ2.53 | โ8.19 | โ7.46 | โ8.87 | โ0.84 |
10 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0.7M | โ | $17.8M | โ | $2.0M | $6.0M | $7.5M | $33.5M | $27.9M | $72.8M |
| Gross profit | $0.5M | โ | $16.8M | โ | $1.9M | $5.3M | $6.5M | $31.5M | $19.9M | $63.5M |
| Research and development | $24.5M | $28.6M | $30.3M | $19.8M | $22.8M | $28.7M | $30.6M | $34.5M | $24.8M | $22.8M |
| Operating income | โ$32.6M | โ$37.4M | โ$23.2M | โ$28.9M | โ$31.5M | โ$35.1M | โ$35.4M | โ$13.0M | โ$14.9M | $31.3M |
| Pretax income | โ$31.5M | โ$37.1M | โ$22.6M | โ$28.1M | โ$29.7M | โ$34.2M | โ$33.6M | โ$9.8M | โ$9.7M | $35.4M |
| Income tax | $0.0M | โ | โ | โ$0.7M | $0.0M | $0.0M | $0.1M | $9.0M | $4.5M | $0.1M |
| Net income | โ$31.5M | โ$37.1M | โ$22.6M | โ$27.3M | โ$29.7M | โ$34.2M | โ$33.7M | โ$18.8M | โ$14.2M | $35.3M |
| Net income to common | โ | โ | โ | โ | โ | โ | โ | โ$18.8M | โ$14.2M | $35.3M |
| Diluted EPS | โ$0.62 | โ$0.72 | โ$0.41 | โ$0.43 | โ$0.37 | โ$0.41 | โ$0.39 | โ$0.21 | โ$0.16 | $0.38 |
| Diluted shares | 0.05B | 0.05B | 0.06B | 0.06B | 0.08B | 0.08B | 0.09B | 0.09B | 0.09B | 0.09B |
| Cash flow | ||||||||||
| Cash from operations | โ$19.8M | โ$30.7M | โ$13.3M | โ$27.9M | โ$28.3M | โ$22.7M | โ$34.1M | โ$35.9M | $49.6M | $31.6M |
| Capital expenditure | $2.6M | $0.4M | $0.2M | $0.2M | $0.2M | $0.3M | $0.5M | $0.2M | $0.1M | $0.3M |
| Free cash flow | โ$22.4M | โ$31.0M | โ$13.4M | โ$28.0M | โ$28.5M | โ$23.0M | โ$34.6M | โ$36.1M | $49.5M | $31.3M |
| Depreciation and amortization | $1.5M | $1.6M | $1.4M | $1.0M | $0.7M | $0.5M | $0.5M | $0.5M | $0.5M | $0.5M |
| Stock-based compensation | $3.1M | $2.6M | $2.2M | $2.4M | $2.8M | $4.3M | $4.3M | $3.6M | $3.0M | $1.9M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $9.7M | $25.5M | $5.9M | $9.2M | $7.1M | $7.8M | $11.1M | $25.6M | $41.9M | $99.9M |
| Current assets | $62.7M | $31.2M | $46.6M | $45.0M | $129M | $123M | $86.1M | $115M | $106M | $148M |
| Current liabilities | $4.7M | $6.2M | $10.0M | $6.8M | $10.5M | $17.1M | $11.9M | $26.3M | $20.2M | $22.6M |
| Property and equipment, net | $6.0M | $4.6M | $3.4M | $2.3M | $1.7M | $1.7M | $1.5M | $1.2M | $0.9M | $0.7M |
| Total assets | $71.1M | $38.7M | $53.2M | $53.8M | $138M | $132M | $94.2M | $121M | $115M | $157M |
| Total liabilities | $7.6M | $9.4M | $15.9M | $15.4M | $18.5M | $25.5M | $16.5M | $55.8M | $60.1M | $53.8M |
| Shareholders' equity | $63.5M | $29.3M | $37.2M | $38.3M | $120M | $107M | $77.7M | $65.6M | $54.9M | $103M |
| Margins | ||||||||||
| Gross margin | 68.7% | โ | 94.2% | โ | 97.0% | 88.7% | 87.0% | 94.0% | 71.5% | 87.3% |
| Operating margin | โ4,576.3% | โ | โ130.5% | โ | โ1,574.8% | โ584.6% | โ471.7% | โ38.8% | โ53.4% | 43.1% |
| EBITDA margin | โ4,367.8% | โ | โ122.7% | โ | โ1,539.1% | โ576.9% | โ465.2% | โ37.4% | โ51.7% | 43.7% |
| Net margin | โ4,425.0% | โ | โ127.0% | โ | โ1,484.9% | โ570.1% | โ449.3% | โ56.1% | โ51.1% | 48.6% |
| FCF margin | โ3,148.6% | โ | โ75.6% | โ | โ1,424.3% | โ383.1% | โ461.2% | โ107.8% | 177.6% | 43.1% |
| Returns | ||||||||||
| Return on capital employed | โ49.1% | โ114.9% | โ53.8% | โ61.5% | โ24.6% | โ30.5% | โ43.0% | โ13.7% | โ15.7% | 23.4% |
| Return on equity | โ49.6% | โ79.9% | โ67.9% | โ72.4% | โ37.6% | โ30.2% | โ36.5% | โ26.2% | โ23.6% | 44.8% |
| Return on assets | โ44.3% | โ67.5% | โ49.2% | โ51.1% | โ30.9% | โ25.3% | โ29.8% | โ17.4% | โ12.0% | 26.0% |
| Return on tangible equity | โ49.6% | โ126.5% | โ60.7% | โ71.3% | โ24.8% | โ32.1% | โ43.4% | โ28.6% | โ25.9% | 34.4% |
| Growth | ||||||||||
| Revenue growth | โ | โ | โ | โ | โ | 200.0% | 25.0% | 346.1% | โ16.7% | 161.1% |
| FCF growth | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ36.7% |
| Share count change | โ | 0.6% | 8.0% | 15.1% | 25.1% | 5.8% | 2.8% | 1.2% | 2.2% | 4.8% |
| Financial health | ||||||||||
| Current ratio | 13.2x | 5.0x | 4.7x | 6.6x | 12.3x | 7.2x | 7.2x | 4.4x | 5.3x | 6.6x |
| Quick ratio | 13.2x | 5.0x | 4.7x | 6.6x | 12.3x | 7.2x | 7.2x | 4.4x | 5.3x | 6.6x |
| Capital allocation | ||||||||||
| Capex / revenue | 365.0% | โ | 0.9% | โ | 8.3% | 4.9% | 6.4% | 0.5% | 0.4% | 0.4% |
| Stock comp / revenue | 433.1% | โ | 12.2% | โ | 138.6% | 71.3% | 57.7% | 10.6% | 10.8% | 2.6% |
| Quality scores | ||||||||||
| Piotroski F-score | โ | โ | โ | โ | โ | 2.0 | 2.0 | 3.0 | 4.0 | 6.0 |
| Altman Z'' | โ1.4 | โ24.9 | โ16.2 | โ18.1 | 1.7 | โ2.5 | โ8.2 | โ7.5 | โ8.9 | โ0.8 |
| Accruals ratio | โ16.4% | โ11.7% | โ20.3% | 1.0% | โ1.4% | โ8.5% | 0.4% | 15.9% | โ54.0% | 2.7% |
Source: SEC EDGAR XBRL filings (CIK 0001119774). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ not investment advice. Check the original filings before relying on any figure.